Emergent Biosolutions (EBS) Receiving Very Favorable Press Coverage, Report Finds
News headlines about Emergent Biosolutions (NYSE:EBS) have trended very positive recently, Alpha One Sentiment reports. Alpha One, a service of Accern, rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Emergent Biosolutions earned a news impact score of 0.69 on Alpha One’s scale. Alpha One also assigned press coverage about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near term.
These are some of the media headlines that may have effected Alpha One Sentiment’s analysis:
- Emergent BioSolutions Inc.’s (EBS) is at $30.10 per share and Axsome Therapeutics, Inc.’s (AXSM) is listed at $3.75 – Stocks Gallery (stocksgallery.com)
- The Emergent Biosolutions Inc (EBS) Shares Bought by Bowling Portfolio Management LLC – BangaloreWeekly (bangaloreweekly.com)
- The Emergent Biosolutions Inc (EBS) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPS – BangaloreWeekly (bangaloreweekly.com)
- Emergent Biosolutions Inc (EBS) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Emergent BioSolutions Inc. (NYSE:EBS) VC Score Reaches 40 – DARC News (darcnews.com)
Shares of Emergent Biosolutions (NYSE:EBS) traded down 1.15% during mid-day trading on Friday, hitting $30.09. The company had a trading volume of 18,112 shares. Emergent Biosolutions has a one year low of $24.47 and a one year high of $44.38. The company’s 50-day moving average is $29.66 and its 200 day moving average is $30.17. The company has a market capitalization of $1.23 billion, a PE ratio of 23.92 and a beta of 1.02.
Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by $0.08. The firm had revenue of $116.90 million for the quarter, compared to the consensus estimate of $121.30 million. Emergent Biosolutions had a net margin of 9.12% and a return on equity of 10.42%. Emergent Biosolutions’s quarterly revenue was up 13.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.16 earnings per share. On average, equities research analysts forecast that Emergent Biosolutions will post $1.58 EPS for the current fiscal year.
A number of research analysts have commented on the company. Chardan Capital reaffirmed a “buy” rating and issued a $47.00 price objective on shares of Emergent Biosolutions in a report on Monday, January 30th. Zacks Investment Research raised Emergent Biosolutions from a “sell” rating to a “hold” rating in a report on Tuesday, February 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $39.40.
In other news, EVP Adam Havey sold 11,419 shares of the stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $28.62, for a total transaction of $326,811.78. Following the transaction, the executive vice president now directly owns 26,046 shares of the company’s stock, valued at approximately $745,436.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Jerome M. Hauer sold 2,576 shares of the stock in a transaction on Wednesday, March 8th. The shares were sold at an average price of $31.27, for a total value of $80,551.52. Following the transaction, the director now directly owns 17,404 shares in the company, valued at $544,223.08. The disclosure for this sale can be found here. 17.20% of the stock is owned by corporate insiders.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Stock Ratings for Emergent Biosolutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc and related stocks with our FREE daily email newsletter.